ClinicalTrials.gg
TerminatedNCT06024174Updated Jul 22, 2025Results posted

A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

A Phase 1/2 interventional study of BMS-986466 and Adagrasib in Advanced Solid Tumors, sponsored by Bristol-Myers Squibb. Terminated at 9 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-22.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Business objectives have changed

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 155 studies in Biliary Tract Neoplasms with a site in United States — 48 open to participants now, 67 under way, 9 of them phase 3. Biliary Tract Neoplasms · United States.

Enrollment
132nd of 140
5 · median 75
Started
2023
with 13 others
Phase 1/2
31 of 155
14 open now
Registered
116th of 155
by date

Among the 155 studies in Biliary Tract Neoplasms with a site in United States, this one is the 132nd largest by enrollment of the 140 interventional ones that give a count, is one of 14 that started in 2023, is one of 31 in phase 1/2, and was the 116th registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

48 of the 155 studies in Biliary Tract Neoplasms with a site in United States are open now. Recruiting first, the newest first:

43 more — sign in →

All 48 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 140 Biliary Tract Neoplasms studies recruiting now, 80 (57%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies in Biliary Tract Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to find a safe, tolerable, and efficacious dose of BMS-986466 when given orally, in combination with adagrasib with or without cetuximab in participants with advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC), pancreatic duct adenocarcinoma (PDAC), biliary tract cancer (BTC), or colorectal cancer (CRC).

03

Conditions studied

  • Advanced Solid Tumors

Keywords

  • BMS-986466
  • KRAS G12C-mutant
  • Pancreatic duct adenocarcinoma
  • Biliary tract cancer
  • Colorectal cancer
  • Non-small cell lung cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Key Inclusion Criteria:

Part 1:

  • Individuals with a confirmed diagnosis of advanced KRAS G12C mutant NSCLC, CRC, PDAC and BTC that has spread to other parts of the body and cannot be removed surgically, may or may not have received previous treatment with KRAS G12C inhibitors.
  • For NSCLC and CRC: Individuals must have a documented KRAS G12C mutation status from NYS or FDA approved/cleared or CE marked test or, when such result is not available, positive KRAS G12C mutation status should be confirmed by a central laboratory in blood sample collected at the time of screening.
  • For PDAC and BTC: Participants must have a documented KRAS G12Cmutation from NYS or FDA-approved/cleared, or CE-marked test and blood samples will be collected only for retrospective testing.
  • Are to available standard of care treatments.

Part 2:

  • Individuals with a confirmed diagnosis of advanced KRAS G12C-mutant NSCLC (Part 2A) or CRC (Part 2B) that has spread to other parts of the body and cannot be removed surgically and have not received previous treatment with KRAS inhibitors.
  • Individuals must have a documented KRAS G12C mutation from FDA or NYS approved/ cleared or CE marked test or, when such result is not available, positive KRAS G12C mutation status should be confirmed by a central laboratory in blood sample and /or tumor samples collected at the time of screening or from archival (less than 1 year old).
  • Have failed or disease recurrence or are not able to tolerate after at least 1 pervious .

Key Exclusion Criteria:

  • Have tumors with known BARF V600X, PTPN11 or KRASQ61X mutations.
  • Have or any significant heart disease or condition.
  • Receiving any medications that are substrate of or inducers and/ or inhibitors

Note: Other protocol-defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Part 1: DDI Cohort

    Drug: BMS-986466 · Drug: Adagrasib

  • Experimental
    Part 1: Dose Escalation

    Drug: BMS-986466 · Drug: Adagrasib · Drug: Cetuximab

  • Experimental
    Part 2: Dose Expansion

    Drug: BMS-986466 · Drug: Adagrasib · Drug: Cetuximab

Interventions

  • Specified dose on specified days

    Also known as: BBP-398, IACS-15509

  • Specified dose on specified days

    Also known as: MRTX849, KRAZATI®

  • Specified dose on specified days

    Also known as: Erbitux®

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With Dose Limiting Toxicity (DLTs)

    A DLT was defined as: * Death not related to disease progression * Grade (Gr) 4 (Life-threatening) neurotoxicity * Gr 3 (Severe) neurotoxicity of greater than 7 days * Gr 3 neurotoxicity does not revert to baseline within 28 days of the start date of the Grade 3 event * Seizures of grade that do not resolve within 7 days * Gr 4 cytokine release syndrome (CRS) that does not resolve to less than or equal to Gr 3 within 3 days * Gr 3 CRS that does not resolve to less than or equal to Grade 2 within 7 days * Any increase in aspartate aminotransferase (AST) or ALT \\\> 3 Ã- ULN and concurrent increase in total bilirubin \\\> 2 Ã- ULN that is unrelated to CRS and has no other probable reason to explain the combination of increases * Any other Gr 3 or 4 event deemed unexpected by the Investigator and considered a DLT upon evaluation by the safety review committee

    Time frame: Cycle 1 (Each cycle consist of 28 days)

  2. Part 1: Number of Participants With Adverse Events (AEs)

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

    Time frame: From first dose until 100 days after last dose (Up to approximately 5 months)

  3. Part 1: Number of Participants With Serious Adverse Events (SAEs)

    A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability or permanent damage, is a congenital anomaly/birth defect, is an important medical event.

    Time frame: From first dose until 30 days after last dose (Up to approximately 3 months)

  4. Part 1: Number of Participants With AEs Leading to Discontinuation

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatmen

    Time frame: From first dose until 30 days after last dose (Up to approximately 3 months)

  5. Part 1: Number of Participants Who Died

    Death due to any cause was assessed.

    Time frame: From first dose until 100 days after last dose (Up to approximately 5 months)

  6. Part 2 Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    Objective Response Rate (ORR) is defined as the percentage of participants with a confirmed Best overall response of Complete Response (CR) or Partial Response (PR) by RECIST v1.1. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 5 months)

Secondary outcomes

  1. Part 1: Maximum Observed Plasma Concentration (Cmax)

    Blood samples were collected to assess adequate PK profiles. Participants were not enrolled in Part 1a, 1b.

    Time frame: Cycle 1 Day 1 (Each cycle consist of 28 days)

  2. Part 1: Time to Maximum Concentration (Tmax)

    Blood samples were collected to assess adequate PK profiles. Participants were not enrolled in Part 1a, 1b.

    Time frame: Cycle 1 Day 1 (Each cycle consist of 28 days)

  3. Part 1: Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-T])

    Blood samples were collected to assess adequate PK profiles. Participants were not enrolled in Part 1a, 1b.

    Time frame: Cycle 1 Day 1 (Each cycle consist of 28 days)

  4. Part 2-Progression-free Survival (PFS) Assessed by BICR as Per RECIST v1.1

    Progression-Free Survival then (PFS) is defined as the time between the date of randomization and the date of first documented disease progression, based on Investigator assessments (per RECIST v1.1), or death due to any cause, whichever occurs first Calculated using Kaplan-Meier estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 5 months)

  5. Part 2- Disease Control Rate (DCR) Assessed by BICR as Per RECIST v1.1

    Disease Control Rate (DCR) (as per Recists v1.1) is defined as the number of randomized participants who achieve a BOR of confirmed CR, confirmed PR, or stable disease (SD), based on BICR assessments divided by the number of all randomized participants.

    Time frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 5 months)

  6. Part 2- Duration of Response (DOR) Assessed by BICR as Per RECIST v1.1

    Duration of objective response (DoR) is defined as the time between the date of first confirmed response (CR or PR) to the date of the first documented tumor progression (per RECIST 1.1) per BICR assessment, or death due to any cause, whichever occurs first. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 5 months)

  7. Part 2- Time to Response (TTR)

    Time to response (TTR) is defined as the time, in months, from randomization to the first objective documentation of PR or better assessed per BICR. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm.

    Time frame: From randomization untill disease progression or death, whichever occurs first (up to approximately 5 months)

  8. Part 2- Number of Participants With Adverse Events (AEs)

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

    Time frame: From first dose until 100 days after last dose (Up to approximately 5 months)

  9. Part 2- Number of Participants With Serious Adverse Events (SAEs)

    A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability or permanent damage, is a congenital anomaly/birth defect, is an important medical event.

    Time frame: From first dose until 100 days after last dose (Up to approximately 5 months)

  10. Part 2- Number of Participants With AEs Leading to Discontinuation

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

    Time frame: From first dose until 100 days after last dose (Up to approximately 5 months)

  11. Part 2- Number of Participants Who Died

    Death due to any cause was assessed.

    Time frame: From first dose until 100 days after last dose (Up to approximately 5 months)

  12. Part 1a and 1b - Changes From Baseline in Pharmacodynamic Biomarker

    Blood samples were collected for assessing pharmacodynamic parameters.

    Time frame: Baseline and Cycle 1 Day 1 (Each cycle consist of 28 days)

07

Results

Posted Jul 22, 2025

Participant flow

Participant flow — Overall Study
MilestonePart 1: Drug-Drug Interaction (DDI) - BMS986466 10 MG + Adagrasib 400MG BID
Started5
Completed0
Not completed5
Withdrew: Other reasons1
Withdrew: Study terminated by sponsor4

Outcome measures

PrimaryPart 1: Number of Participants With Dose Limiting Toxicity (DLTs)

A DLT was defined as: * Death not related to disease progression * Grade (Gr) 4 (Life-threatening) neurotoxicity * Gr 3 (Severe) neurotoxicity of greater than 7 days * Gr 3 neurotoxicity does not revert to baseline within 28 days of the start date of the Grade 3 event * Seizures of grade that do not resolve within 7 days * Gr 4 cytokine release syndrome (CRS) that does not resolve to less than or equal to Gr 3 within 3 days * Gr 3 CRS that does not resolve to less than or equal to Grade 2 within 7 days * Any increase in aspartate aminotransferase (AST) or ALT \\\> 3 Ã- ULN and concurrent increase in total bilirubin \\\> 2 Ã- ULN that is unrelated to CRS and has no other probable reason to explain the combination of increases * Any other Gr 3 or 4 event deemed unexpected by the Investigator and considered a DLT upon evaluation by the safety review committee

Time frame:
Cycle 1 (Each cycle consist of 28 days)
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Dose Limiting Toxicity (DLTs)
ParticipantsPart 1: Drug-Drug Interaction (DDI) - BMS986466 10 MG + Adagrasib 400MG BID
Part 1: Number of Participants With Dose Limiting Toxicity (DLTs)0
PrimaryPart 1: Number of Participants With Adverse Events (AEs)

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

Time frame:
From first dose until 100 days after last dose (Up to approximately 5 months)
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Adverse Events (AEs)
ParticipantsPart 1: Drug-Drug Interaction (DDI) - BMS986466 10 MG + Adagrasib 400MG BID
Part 1: Number of Participants With Adverse Events (AEs)4
PrimaryPart 1: Number of Participants With Serious Adverse Events (SAEs)

A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability or permanent damage, is a congenital anomaly/birth defect, is an important medical event.

Time frame:
From first dose until 30 days after last dose (Up to approximately 3 months)
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Serious Adverse Events (SAEs)
ParticipantsPart 1: Drug-Drug Interaction (DDI) - BMS986466 10 MG + Adagrasib 400MG BID
Part 1: Number of Participants With Serious Adverse Events (SAEs)1
PrimaryPart 1: Number of Participants With AEs Leading to Discontinuation

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatmen

Time frame:
From first dose until 30 days after last dose (Up to approximately 3 months)
Reported as:
Count of participants · Participants
Part 1: Number of Participants With AEs Leading to Discontinuation
ParticipantsPart 1: Drug-Drug Interaction (DDI) - BMS986466 10 MG + Adagrasib 400MG BID
Part 1: Number of Participants With AEs Leading to Discontinuation0
PrimaryPart 1: Number of Participants Who Died

Death due to any cause was assessed.

Time frame:
From first dose until 100 days after last dose (Up to approximately 5 months)
Reported as:
Count of participants · Participants
Part 1: Number of Participants Who Died
ParticipantsPart 1: Drug-Drug Interaction (DDI) - BMS986466 10 MG + Adagrasib 400MG BID
Part 1: Number of Participants Who Died0
PrimaryPart 2 Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

Objective Response Rate (ORR) is defined as the percentage of participants with a confirmed Best overall response of Complete Response (CR) or Partial Response (PR) by RECIST v1.1. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From randomization untill disease progression or death, whichever occurs first (up to approximately 5 months)

No measurements were reported for this outcome.

SecondaryPart 1: Maximum Observed Plasma Concentration (Cmax)

Blood samples were collected to assess adequate PK profiles. Participants were not enrolled in Part 1a, 1b.

Time frame:
Cycle 1 Day 1 (Each cycle consist of 28 days)
Reported as:
Geometric mean · ng/mL
Part 1: Maximum Observed Plasma Concentration (Cmax)
ng/mLPart 1: Drug-Drug Interaction (DDI) - BMS986466 10 MG + Adagrasib 400MG BID
Part 1: Maximum Observed Plasma Concentration (Cmax)NA ± NA
SecondaryPart 1: Time to Maximum Concentration (Tmax)

Blood samples were collected to assess adequate PK profiles. Participants were not enrolled in Part 1a, 1b.

Time frame:
Cycle 1 Day 1 (Each cycle consist of 28 days)
Reported as:
Geometric mean · hours
Part 1: Time to Maximum Concentration (Tmax)
hoursPart 1: Drug-Drug Interaction (DDI) - BMS986466 10 MG + Adagrasib 400MG BID
Part 1: Time to Maximum Concentration (Tmax)NA ± NA
SecondaryPart 1: Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-T])

Blood samples were collected to assess adequate PK profiles. Participants were not enrolled in Part 1a, 1b.

Time frame:
Cycle 1 Day 1 (Each cycle consist of 28 days)
Reported as:
Geometric mean · mcg*hr/mL
Part 1: Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-T])
mcg*hr/mLPart 1: Drug-Drug Interaction (DDI) - BMS986466 10 MG + Adagrasib 400MG BID
Part 1: Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-T])NA ± NA
SecondaryPart 2-Progression-free Survival (PFS) Assessed by BICR as Per RECIST v1.1

Progression-Free Survival then (PFS) is defined as the time between the date of randomization and the date of first documented disease progression, based on Investigator assessments (per RECIST v1.1), or death due to any cause, whichever occurs first Calculated using Kaplan-Meier estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From randomization untill disease progression or death, whichever occurs first (up to approximately 5 months)

No measurements were reported for this outcome.

SecondaryPart 2- Disease Control Rate (DCR) Assessed by BICR as Per RECIST v1.1

Disease Control Rate (DCR) (as per Recists v1.1) is defined as the number of randomized participants who achieve a BOR of confirmed CR, confirmed PR, or stable disease (SD), based on BICR assessments divided by the number of all randomized participants.

Time frame:
From randomization untill disease progression or death, whichever occurs first (up to approximately 5 months)

No measurements were reported for this outcome.

SecondaryPart 2- Duration of Response (DOR) Assessed by BICR as Per RECIST v1.1

Duration of objective response (DoR) is defined as the time between the date of first confirmed response (CR or PR) to the date of the first documented tumor progression (per RECIST 1.1) per BICR assessment, or death due to any cause, whichever occurs first. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
From randomization untill disease progression or death, whichever occurs first (up to approximately 5 months)

No measurements were reported for this outcome.

SecondaryPart 2- Time to Response (TTR)

Time to response (TTR) is defined as the time, in months, from randomization to the first objective documentation of PR or better assessed per BICR. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm.

Time frame:
From randomization untill disease progression or death, whichever occurs first (up to approximately 5 months)

No measurements were reported for this outcome.

SecondaryPart 2- Number of Participants With Adverse Events (AEs)

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

Time frame:
From first dose until 100 days after last dose (Up to approximately 5 months)

No measurements were reported for this outcome.

SecondaryPart 2- Number of Participants With Serious Adverse Events (SAEs)

A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability or permanent damage, is a congenital anomaly/birth defect, is an important medical event.

Time frame:
From first dose until 100 days after last dose (Up to approximately 5 months)

No measurements were reported for this outcome.

SecondaryPart 2- Number of Participants With AEs Leading to Discontinuation

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

Time frame:
From first dose until 100 days after last dose (Up to approximately 5 months)

No measurements were reported for this outcome.

SecondaryPart 2- Number of Participants Who Died

Death due to any cause was assessed.

Time frame:
From first dose until 100 days after last dose (Up to approximately 5 months)

No measurements were reported for this outcome.

SecondaryPart 1a and 1b - Changes From Baseline in Pharmacodynamic Biomarker

Blood samples were collected for assessing pharmacodynamic parameters.

Time frame:
Baseline and Cycle 1 Day 1 (Each cycle consist of 28 days)

No measurements were reported for this outcome.

Adverse events

Collected over All cause mortality, and serious and non-serious adverse events were collected from from first dose until 100 days after last dose (Up to approximately 5 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Drug-Drug Interaction (DDI) - BMS986466 10 MG + Adagrasib 400MG BID0/5 (0%)1/5 (20%)4/5 (80%)
Most frequent serious events
Most frequent serious events
EventPart 1: Drug-Drug Interaction (DDI) - BMS986466 10 MG + Adagrasib 400MG BID
PyrexiaGeneral disorders1/5
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPart 1: Drug-Drug Interaction (DDI) - BMS986466 10 MG + Adagrasib 400MG BID
ConstipationGastrointestinal disorders2/5
DiarrhoeaGastrointestinal disorders2/5
NauseaGastrointestinal disorders2/5
Epigastric discomfortGastrointestinal disorders1/5
ProctalgiaGastrointestinal disorders1/5
VomitingGastrointestinal disorders1/5
FatigueGeneral disorders1/5
Alanine aminotransferase increasedInvestigations1/5
Amylase increasedInvestigations1/5
Aspartate aminotransferase increasedInvestigations1/5

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part 1: Drug-Drug Interaction (DDI) - BMS986466 10 MG + Adagrasib 400MG BID
Mean55.2 ± 7.16
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Drug-Drug Interaction (DDI) - BMS986466 10 MG + Adagrasib 400MG BID
Female2
Male3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Drug-Drug Interaction (DDI) - BMS986466 10 MG + Adagrasib 400MG BID
Hispanic or Latino0
Not Hispanic or Latino4
Unknown or Not Reported1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: Drug-Drug Interaction (DDI) - BMS986466 10 MG + Adagrasib 400MG BID
BLACK OR AFRICAN AMERICAN1
WHITE4
08

Study locations

9 sites
  • Local Institution - 0047
    Los Angeles, California 90067, United States
  • Local Institution - 0040
    Athens, Georgia 30607, United States
  • Local Institution - 0025
    Hackensack, New Jersey 07601, United States
  • Local Institution - 0008
    Morristown, New Jersey 07960, United States
  • Local Institution - 0053
    Westmead, New South Wales 2145, Australia
  • Local Institution - 0083
    Helsinki, 00029, Finland
  • Local Institution - 0020
    Lille, 59037, France
  • Local Institution - 0082
    Petah Tikva, Central District 4941492, Israel
  • Local Institution - 0081
    Tel Aviv, Tell Abīb 6423906, Israel
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in May 2024, 6 months.

Results were first posted in Jul 2025, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2023
First posted
Sep 6, 2023
StartActual
Nov 9, 2023
Primary completionActual
May 13, 2024
CompletionActual
May 13, 2024
Results first posted
Jul 22, 2025
Last update
Jul 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06024174
Responsible party
Sponsor
First posted
Sep 6, 2023
Start date
Nov 9, 2023
Primary completion
May 13, 2024
Completion
May 13, 2024
Results posted
Jul 22, 2025
Last update
Jul 22, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: BBP-398 · Adagrasib

Start the discussion